Uncategorized
Allergan Receives FDA Approval for Lumigan 0.01%
Allergan, Inc. (Irvine, CA), announced that the FDA has
approved Lumigan 0.01% as a first-line therapy to reduce
elevated IOP in patients with open-angle glaucoma or ocular
hypertension. Lumigan 0.01%, a bimatoprost ophthalmic
solution, is a reformulation of Lumigan 0.03%.
“Once-a-day prostaglandins are becoming a th...